AU2002231277B2 - Neurotrophic tacrolimus analogs - Google Patents

Neurotrophic tacrolimus analogs Download PDF

Info

Publication number
AU2002231277B2
AU2002231277B2 AU2002231277A AU2002231277A AU2002231277B2 AU 2002231277 B2 AU2002231277 B2 AU 2002231277B2 AU 2002231277 A AU2002231277 A AU 2002231277A AU 2002231277 A AU2002231277 A AU 2002231277A AU 2002231277 B2 AU2002231277 B2 AU 2002231277B2
Authority
AU
Australia
Prior art keywords
injury
compound
spinal cord
disease
nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002231277A
Other languages
English (en)
Other versions
AU2002231277A1 (en
Inventor
Bruce Gold
Nobuya Matsuoka
Takayuki Yamaji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AU2002231277A1 publication Critical patent/AU2002231277A1/en
Assigned to ASTELLAS PHARMA, INC. reassignment ASTELLAS PHARMA, INC. Request for Assignment Assignors: FUJISAWA PHARMACEUTICAL CO., LTD.
Application granted granted Critical
Publication of AU2002231277B2 publication Critical patent/AU2002231277B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)
AU2002231277A 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs Ceased AU2002231277B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
US60/258,500 2000-12-29
PCT/US2001/050419 WO2002053159A1 (en) 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs

Publications (2)

Publication Number Publication Date
AU2002231277A1 AU2002231277A1 (en) 2003-01-23
AU2002231277B2 true AU2002231277B2 (en) 2006-11-30

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002231277A Ceased AU2002231277B2 (en) 2000-12-29 2001-12-31 Neurotrophic tacrolimus analogs

Country Status (18)

Country Link
EP (1) EP1353671A4 (ko)
JP (1) JP2004527472A (ko)
KR (2) KR100794204B1 (ko)
CN (1) CN1293877C (ko)
AR (1) AR035411A1 (ko)
AU (1) AU2002231277B2 (ko)
BR (1) BR0116762A (ko)
CA (1) CA2433384A1 (ko)
CZ (1) CZ20032060A3 (ko)
HU (1) HUP0302521A3 (ko)
IL (1) IL156664A0 (ko)
MX (1) MXPA03005941A (ko)
NO (1) NO20032913D0 (ko)
NZ (1) NZ527209A (ko)
PL (1) PL366301A1 (ko)
RU (1) RU2288716C2 (ko)
WO (1) WO2002053159A1 (ko)
ZA (1) ZA200305806B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
JP2007518692A (ja) * 2004-01-20 2007-07-12 アステラス製薬株式会社 勃起不全治療方法
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
CA2730751A1 (en) * 2008-07-23 2010-01-28 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
EP2817009A1 (en) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323042A1 (en) * 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
WO1994004148A1 (en) * 1992-08-25 1994-03-03 Fisons Plc Use of macrolide compounds for the treatment of reversible obstructive airways disease
AU6003900A (en) * 1999-07-21 2001-02-05 Fujisawa Pharmaceutical Co., Ltd. New use of a macrolide compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323042A1 (en) * 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
WO1994004148A1 (en) * 1992-08-25 1994-03-03 Fisons Plc Use of macrolide compounds for the treatment of reversible obstructive airways disease
AU6003900A (en) * 1999-07-21 2001-02-05 Fujisawa Pharmaceutical Co., Ltd. New use of a macrolide compound

Also Published As

Publication number Publication date
EP1353671A1 (en) 2003-10-22
KR100794204B1 (ko) 2008-01-14
CA2433384A1 (en) 2002-07-11
NO20032913D0 (no) 2003-06-24
AR035411A1 (es) 2004-05-26
HUP0302521A3 (en) 2007-03-28
KR20070030331A (ko) 2007-03-15
CN1538843A (zh) 2004-10-20
JP2004527472A (ja) 2004-09-09
ZA200305806B (en) 2005-01-26
EP1353671A4 (en) 2004-07-14
NZ527209A (en) 2005-09-30
CN1293877C (zh) 2007-01-10
RU2288716C2 (ru) 2006-12-10
HUP0302521A2 (hu) 2003-11-28
RU2003123493A (ru) 2005-01-20
MXPA03005941A (es) 2005-02-14
CZ20032060A3 (cs) 2004-01-14
KR20040007431A (ko) 2004-01-24
IL156664A0 (en) 2004-01-04
PL366301A1 (en) 2005-01-24
WO2002053159A1 (en) 2002-07-11
BR0116762A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
Gaviria et al. Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats
Cui et al. CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters.
KR100298808B1 (ko) 외상손상과관련된신경학적병변의치료를위한,릴루졸을포함하는제약학적조성물
Yin et al. Taxol-modified collagen scaffold implantation promotes functional recovery after long-distance spinal cord complete transection in canines
Geisler et al. GM-1 ganglioside in human spinal cord injury
MX2009002063A (es) Tratamiento de desordenes en cartilagos con factor de crecimiento de fibroblastos-18.
DE69635754T2 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
AU2002231277B2 (en) Neurotrophic tacrolimus analogs
US20010018530A1 (en) Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
AU2002231277A1 (en) Neurotrophic tacrolimus analogs
CN1310622A (zh) 丙戊酸类似物在治疗和预防偏头痛与情感性疾病中的应用
KR20200101948A (ko) 신경계 질환 치료제
US20040077676A1 (en) Neurotrophic tacrolimus analogs
y Ribotta et al. Strategies for regeneration and repair in spinal cord traumatic injury
US6284771B1 (en) Method for treating schizophrenia
WO2017057562A1 (ja) 末梢神経障害又は脊髄損傷の治療剤及び／又は予防剤
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
Itoh et al. The effect of neurotrophic pyrimidine heterocyclic compounds, MS-818 and MS-430, on the regeneration of injured peripheral nerves
US6476001B1 (en) Facilitation of repair of neural injury with CM101/GBS toxin
EP3362059B1 (en) New combination therapies for treating neurological damage
US6852496B1 (en) Methods of screening for agents that promote nerve cell growth
Tessler et al. Neural transplantation: Spinal cord
MXPA00002395A (en) Method of increasing bone volume
MXPA97009163A (en) The use of a dopamine / proluctine reduction compound to prepare compositions to prevent associated stenosis with intervention after invasive interventions without deriva

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: ASTELLAS PHARMA, INC.

Free format text: FORMER NAME: FUJISAWA PHARMACEUTICAL CO., LTD.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired